TRPC1 | Transient Receptor Potential Cation Channel Subfamily C Member 1

Family:
Transient receptor potential channels

Subgroups:
TRPC (TRPC1–TRPC7), TRPV (TRPV1-TRPV6), TRPA1, TRPM (TRPM1–TRPM8), TRPP (TRPP1–TRPP3, PKD1, PKDREJ, PKDL1–PKDL3), TRPML (TRPML1–TRPML3), TRPN

Topology:
Most TRP channels are composed of 6 transmembrane domains (helices) with intracellular N- and C-termini, non-selectively permeable to various cations

TRPC1: Background information

TRPC1, also called Short transient receptor potential channel 1 or Transient Receptor Protein 1, was the first mammalian Transient Receptor Potential channel to be identified. TRPC1 is a nonspecific cation channel, which means that both sodium and calcium ions can pass through it. TRPC1 is thought to mediate calcium entry in response to depletion of endoplasmic calcium stores or activation of receptors coupled to the phospholipase C system.

Gene:
TRPC1

Human Protein:
UniProt P48995

Tissue:
Ubiquitous expressed, vascular smooth mucle cells, endothelial cells

Function/ Application:
Regulation of cytosolic calcium ion concentration

Pathology:
Diabetic nephropathy, Parkinson's disease, Huntington's disease, Duchenne muscular dystrophy, cancer, seizures, Darier-White skin disease

Interaction:
TRPC3, TRPC4, TRPC5, TRPC7, STIM1, polycystic kidney disease 2, Homer protein homolog 3, Ras homolog gene family, member A (RhoA), inositol 1,4,5 triphosphate, Bone morphogenetic protein receptor, type IB

Modulator:
Thapsigargin, lanthanum, Optovin, gadolinium, SKF96365

Assays:
Patch Clamp: whole cell, extracellular perfusion

Recommended Reviews:
International Union of Pharmacology. XLIII. Compendium of voltage-gated ion channels: transient receptor potential channels., Pharmacol Rev 55(4):591-6 Clapham, et al. 2003

Data and Applications

TRPC1 (Smooth Muscle Cells) - Pharmacology

Patchliner data and applications:
Data are taken from Li, J. et al., Circulation Research, 2008,103(8), e97-104.

(a) Example whole cell recording showing current evoked by extracellular application of 2 μM thapsigargin (TG) and subsequent inhibition by 10 μM lanthanum (La³⁺). (b) As for (a) but showing the effect of 20 μg/ml anti-STIM1 antibody. (c) For the experiment shown in (b), curren voltage relationships for the current evoked by TG and blocked by anti-STIM1 antibody. (d) Mean currents normalized to pre-antibody values showing the effect of 20 μg/ml ani-STIM1 antibody and lack of effects for IgG or denatured anti-STIM1 antibody.

Publications

2019 - Inhibition of Polyamine Biosynthesis Reverses Ca2+ Channel Remodeling in Colon Cancer Cells

Port-a-Patch publication in Cancers (2019)

Authors:
Gutiérrez L.G., Hernández-Morales M., Núñez L., Villalobos C.

2018 - Electrophysiological experiments in microgravity: lessons learned and future challenges

Port-a-Patch publication in Microgravity (2018)

Authors:
Wuest S.L., Gantenbein B., Ille F.,Egli M.

2017 - Mitochondria sustain store-operated currents in colon cancer cells but not in normal colonic cells: reversal by non-steroidal anti-inflammatory drugs

Port-a-Patch publication in Oncotarget (2017)

Authors:
Hernández-Morales M., Sobradillo D., Valero R.A., Muñoz E., Ubierna D., Moyer M.P., Núñez L., Villalobos C.

2008 - TRPC channel activation by extracellular thioredoxin

Patchliner publication in Nature (2008)

Authors:
Xu S.Z., Sukumar P., Zeng F., Li J., Jairaman A., English A., Naylor J., Ciurtin C., Majeed Y., Milligan C.J., Bahnasi Y.M., Al-Shawaf E., Porter K.E., Jiang L.H., Emery P., Sivaprasadarao A., Beech D.J.

2008 - Interactions, functions, and independence of plasma membrane STIM1 and TRPC1 in vascular smooth muscle cells

Patchliner publication in Circulation Research (2008)

Authors:
Li J., Sukumar P., Milligan C.J., Kumar B., Ma Z.Y., Munsch C.M., Jiang L.H., Porter K.E., Beech D.J.